Epidemiology and biology of relapse after stem cell transplantation.
作者信息
Horowitz Mary, Schreiber Hans, Elder Alex, Heidenreich Olaf, Vormoor Josef, Toffalori Christina, Vago Luca, Kröger Nicolaus
机构信息
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Pathology, The University of Chicago, Chicago, IL, USA.
出版信息
Bone Marrow Transplant. 2018 Nov;53(11):1379-1389. doi: 10.1038/s41409-018-0171-z. Epub 2018 Apr 18.
Abstract
摘要
相似文献
1
Epidemiology and biology of relapse after stem cell transplantation.干细胞移植后复发的流行病学与生物学特性
Bone Marrow Transplant. 2018 Nov;53(11):1379-1389. doi: 10.1038/s41409-018-0171-z. Epub 2018 Apr 18.
2
Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.第三届干细胞移植后复发的生物学、预防及治疗国际研讨会
Bone Marrow Transplant. 2018 Jan;53(1):1-2. doi: 10.1038/bmt.2017.218. Epub 2017 Oct 9.
3
Prevention and treatment of relapse after stem cell transplantation with immunotherapy.免疫疗法防治干细胞移植后复发。
Bone Marrow Transplant. 2018 Jun;53(6):664-672. doi: 10.1038/s41409-018-0232-3. Epub 2018 May 24.
4
Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation.验证研究未能证实碱基切除修复途径中的基因变异与造血细胞移植后移植相关死亡率及复发之间存在关联。
Biol Blood Marrow Transplant. 2016 Aug;22(8):1531-1532. doi: 10.1016/j.bbmt.2016.04.020. Epub 2016 May 4.
5
High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma.多发性骨髓瘤异基因造血干细胞移植后复发采用大剂量化疗联合自体干细胞救援治疗。
Bone Marrow Transplant. 2011 Aug;46(8):1156-7. doi: 10.1038/bmt.2010.251. Epub 2010 Oct 25.
6
The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.减低剂量预处理造血干细胞移植后循环自然杀伤细胞与无复发生存及移植物抗宿主病的关系
Haematologica. 2008 Dec;93(12):1852-8. doi: 10.3324/haematol.13033. Epub 2008 Oct 22.
7
Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.自体移植后复发的霍奇金淋巴瘤：采用减低剂量预处理策略及T细胞去除加T细胞回输的异基因造血干细胞移植
Eur J Haematol. 2009 Sep;83(3):273-5. doi: 10.1111/j.1600-0609.2009.01282.x. Epub 2009 Jun 2.
8
Autologous peripheral blood stem cell transplantation using G-CSF combined conditioning in AML patients: delayed platelet recovery and frequency early relapse.使用粒细胞集落刺激因子联合预处理的急性髓系白血病患者自体外周血干细胞移植：血小板恢复延迟及早期复发频率
Bone Marrow Transplant. 2000 Aug;26(4):459-60. doi: 10.1038/sj.bmt.1702513.
9
Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?用于预测接受异基因造血细胞移植的急性髓系白血病患者预后的事件发生时间比？
Biol Blood Marrow Transplant. 2017 Oct;23(10):1804-1808. doi: 10.1016/j.bbmt.2017.06.016. Epub 2017 Jul 5.
10
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.伊达比星强化的BUCY2预处理方案改善了接受异基因造血干细胞移植的高危急性髓系白血病患者的生存率，但对淋巴细胞白血病患者无效：一项回顾性比较研究。
Leuk Res. 2016 Jul;46:61-8. doi: 10.1016/j.leukres.2016.04.014. Epub 2016 Apr 19.
引用本文的文献
1
Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.新诊断急性髓系白血病（AML）的适合与不适合患者治疗选择的最新进展
Curr Treat Options Oncol. 2025 Aug 23. doi: 10.1007/s11864-025-01351-3.
2
Prognostic factors of survival in second allogeneic hematopoietic transplantation.第二次异基因造血移植生存的预后因素
Ann Hematol. 2025 Jun;104(6):3447-3450. doi: 10.1007/s00277-025-06469-w. Epub 2025 Jun 24.
3
Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.移植前流式细胞术、WT1表达和二代测序相结合用于微小残留病监测，在预测接受异基因移植的急性髓系白血病患者的预后方面很有效。
Ann Hematol. 2025 Apr 28. doi: 10.1007/s00277-025-06384-0.
4
Reduced incidence of relapse and graft--host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后急性髓系白血病复发率及移植物抗宿主病发生率降低。
Haematologica. 2025 Sep 1;110(9):1998-2008. doi: 10.3324/haematol.2025.287390. Epub 2025 Apr 10.
5
IFN-γ and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation.干扰素-γ与供体白细胞输注用于异基因造血干细胞移植后复发的髓母细胞性恶性肿瘤
JCI Insight. 2025 Mar 25;10(9). doi: 10.1172/jci.insight.190655. eCollection 2025 May 8.
6
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后供体淋巴细胞输注后的HLA进化分歧评分
Hemasphere. 2025 Feb 13;9(2):e70088. doi: 10.1002/hem3.70088. eCollection 2025 Feb.
7
A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.异基因造血细胞移植9年后供体细胞来源血液系统肿瘤的病例报告
Oncotarget. 2025 Feb 5;16:44-50. doi: 10.18632/oncotarget.28686.
8
Maintenance strategies for relapse prevention and treatment.预防复发和治疗的维持策略。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):635-643. doi: 10.1182/hematology.2024000589.
9
Biology of post-transplant relapse: actionable features.移植后复发的生物学：可采取行动的特征。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):736-743. doi: 10.1182/hematology.2024000588.
10
A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis.钙调磷酸酶抑制剂同种异体造血干细胞移植后神经毒性的疑难病例：细胞毒性 T 淋巴细胞相关蛋白 4-免疫球蛋白阻断用于移植物抗宿主病预防的成功新方案。
Cell Transplant. 2024 Jan-Dec;33:9636897241265249. doi: 10.1177/09636897241265249.
本文引用的文献
1
NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.亲缘半相合造血干细胞移植后应用环磷酰胺后 NK 细胞的恢复：动力学及其临床意义。
Blood. 2018 Jan 11;131(2):247-262. doi: 10.1182/blood-2017-05-780668. Epub 2017 Oct 6.
2
Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.髓系恶性肿瘤中的间充质干细胞：聚焦免疫逃逸及治疗意义
Stem Cells Int. 2017;2017:6720594. doi: 10.1155/2017/6720594. Epub 2017 Aug 21.
3
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
4
An immunogenic personal neoantigen vaccine for patients with melanoma.一种用于黑色素瘤患者的免疫原性个人新抗原疫苗。
Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
5
A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.一种用于快速、可靠诊断异基因造血干细胞移植后HLA丢失复发的新工具。
Blood. 2017 Sep 7;130(10):1270-1273. doi: 10.1182/blood-2017-05-784306. Epub 2017 Jun 27.
6
Current Use and Trends in Hematopoietic Cell Transplantation in the United States.美国造血细胞移植的当前应用与趋势
Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421. doi: 10.1016/j.bbmt.2017.05.035. Epub 2017 Jun 9.
7
Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.丰富且具有同等效力的起始细胞引发并维持急性淋巴细胞白血病。
Leukemia. 2017 Dec;31(12):2577-2586. doi: 10.1038/leu.2017.140. Epub 2017 May 10.
8
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.干扰素-γ引起的肿瘤缺血类似于生理性血管消退。
Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.
9
Hematopoietic stem cell transplantation and cellular therapy.造血干细胞移植和细胞疗法。
HLA. 2017 May;89(5):267-277. doi: 10.1111/tan.13005.
10
Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.单倍体相合干细胞移植的应用持续增加：2015年欧洲血液和骨髓移植学会活动调查报告。
Bone Marrow Transplant. 2017 Jun;52(6):811-817. doi: 10.1038/bmt.2017.34. Epub 2017 Mar 13.
Zotero 插件